. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: J Viral Hepat. 2014 Nov 24;22(8):675–681. doi: 10.1111/jvh.12368

Table 2.

Patient characteristics stratified by duration of ETV monotherapy before switch to an alternate therapy (TDF monotherapy or ETV+TDF combination therapy) in patients with a partial virological response to ETV

	ETV Treatment ≤ 2 years (n = 36)	ETV Treatment > 2 years (n = 32)	p-value
Median age (years)	40 (19 - 68)	40 (20 - 75)	0.21
Male	69%	56%	0.26
HBeAg positive	92%	94%	0.74
Prior treatment	28%	34%	0.56
Naïve HBV DNA (log₁₀ IU/mL)	7.78 ± 1.12	8.00 ± 0.86	0.43
Pre-ETV monotherapy
HBV DNA (log₁₀ IU/mL)	7.35 ± 1.28	7.31 ± 1.91	0.91
Median ALT (IU/L)	49 (8 - 156)	51 (19 - 99)	0.91
At Switch
HBV DNA (log₁₀ IU/mL)	3.61 ± 1.04	3.15 ± 0.76	0.04
Median ALT (IU/L)	28 (12 - 75)	26 (9 - 63)	0.89

ETV, entecavir; TDF, tenofovir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase